- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.10. | Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million | 888 | GlobeNewswire (Europe) | Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera's dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The... ► Artikel lesen | |
| 21.10. | Galera Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 03.09. | Galera Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.08. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 15.05. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| GALERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 31.12.24 | Galera Therapeutics completes acquisition of Nova Pharmaceuticals | 467 | GlobeNewswire (Europe) | Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,000 | -0,77 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 56,50 | +1,80 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| MAINZ BIOMED | 1,460 | -2,67 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed to Attend 2025 Maxim Growth Summit | Issuer: Mainz BioMed N.V.
/ Key word(s): Conference
Mainz Biomed to Attend 2025 Maxim Growth Summit
15.10.2025 / 15:01 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,390 | +2,57 % | FDA-Sonderstatus für Krebstherapie beflügelt Cellectar-Aktie | ||
| GALAPAGOS NV | 27,380 | -0,65 % | Galapagos NV: Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development | New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board
Mechelen, Belgium; October 30, 2025, 21:01 CET - Galapagos NV (Euronext & NASDAQ:... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,992 | -1,63 % | Cardiff Oncology: Neue Impulse voraus? | Mit der Aktie von Cardiff Oncology haben Mitglieder von sharedealsPlus in der Vergangenheit mehrfach hervorragend verdient. Zuletzt konnten im Rahmen eines Daten-Run-up-Szenarios über 30% Kursgewinn... ► Artikel lesen | |
| NOVOCURE | 11,085 | -0,22 % | Novocure Posts Wider Loss In Q3 | WASHINGTON (dpa-AFX) - Novocure (NVCR) reported a third quarter net loss of $37.3 million compared to a loss of $30.6 million, prior year. Net loss per ordinary share was $0.33 compared to a... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 9,570 | 0,00 % | Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value | BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics... ► Artikel lesen | |
| CYTOKINETICS | 54,50 | -1,80 % | Cytokinetics, Incorporated: Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 | ||
| CYTOMX THERAPEUTICS | 3,110 | +0,26 % | CytomX Therapeutics Inc.: CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
| SPERO THERAPEUTICS | 2,050 | -3,07 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
| EIGER BIOPHARMACEUTICALS | 5,840 | -100,00 % | Eiger Express Permian-to-Gulf Coast natural gas pipeline will proceed, partners say | ||
| VANDA PHARMACEUTICALS | 3,800 | -1,04 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results | Fanapt® Q3 2025 net product sales increased by 31% to $31.2 million compared to Q3 2024
BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,640 | +2,82 % | Minerva Neurosciences: NBC-Tipp wird zum Tenbagger! | Anfang des Monats berichteten wir über hohe Preissprünge bei der Aktie von Minerva Neurosciences. Jetzt ist klar: Das anfängliche Kursspektakel bei der Biotech-Empfehlung des No Brainer Club war lediglich... ► Artikel lesen |
Das Unternehmen GALERA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GALERA THERAPEUTICS INC finden Sie auf Wallstreet Online.